MARCH 23 - 26, 2026
Join us at DCAT Week
Afton Scientific is excited to connect with industry leaders at DCAT Week 2026! As a trusted partner in sterile manufacturing and aseptic processing, we’re looking forward to discussing how our expertise, advanced facilities, and commitment to quality can help bring your pharmaceutical products to market with confidence. Let’s schedule a time to meet and explore opportunities for collaboration.
A Sterile Fill/Finish CDMO Built for Long-Term Partnership
For more than 20 years, we’ve focused exclusively on sterile fill/finish, supporting clinical and commercial programs with a strong quality record and high-touch engagement.
- Long-tenured teams with deep sterile expertise
- Small & large molecule expertise
- Proven quality systems and execution
- Flexible capacity to support evolving programs
- US-based manufacturing operations
With capacity available and a new Annex 1-compliant, isolator-based filling line coming online in 2026, we help our partners plan with confidence for both near-term needs and future growth.
A More Hands-On Approach to Sterile Fill/Finish
Built around partnership, accountability, and trust.
How We Partner
- Collaborative by design
- High-touch, senior-level engagement
- Clear, direct communication
How We Execute
- Quality-led decision making
- Well-controlled processes
- Reliable, disciplined execution
An experienced, steady partner for sterile fill/finish programs at every stage.
Michael Dunn, CCO
Michael is the Chief Commercial Officer at Afton Scientific, a specialized sterile injectable CDMO providing aseptic manufacturing and fill-finish services for biologics and small molecules. With more than 20 years of leadership experience in pharmaceutical and biotech CDMOs, he has led global commercial and business development teams across North America, Europe, and Asia, driving strategic growth, new partnerships, and successful product launches. At DCAT Week, Michael will share how Afton Scientific partners with innovators to expand sterile fill/finish capacity, accelerate clinical and commercial programs, and deliver high‑quality injectable drug products with a flexible, customer‑first approach.
Tom Thorpe, CEO
Tom is the founder and CEO of Afton Scientific, a specialized sterile injectable CDMO he has led since 1991 to support small‑batch clinical and commercial manufacturing for innovators worldwide. With 45 years of experience spanning pharmaceutical operations, entrepreneurial ventures, and investment banking, he has guided Afton’s evolution from a bootstrapped start‑up to a scaling organization investing over $200 million in new isolator-based capacity and advanced fill‑finish infrastructure. At DCAT Week, Tom will highlight how a trust‑first, quality‑driven culture and direct access to leadership enable Afton to be a nimble, high‑touch partner for sterile injectable programs from early development through commercial supply.
David Pereira, COO
David is Chief Operating Officer at Afton Scientific, where he oversees operations, finance, and strategic execution as the company expands its sterile injectable CDMO capabilities and global customer base. With nearly two decades at Afton in roles spanning director of operations, COO, and COO/CFO, he brings deep expertise in scaling manufacturing, optimizing processes, and aligning investment with long‑term growth. For DCAT Week, David will focus on how Afton’s new Annex I–aligned capacity and flexible fill‑finish platforms help sponsors bridge the clinical‑to‑commercial gap while maintaining rigorous quality, reliability, and patient focus.
